Inovio Pharmaceuticals, Inc. (INO)

5.45 + 0.09 (+1.68%) At close: 4:00PM EDT

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267-440-4200
http://www.inovio.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 239

Key Executives

Name	Title	Pay	Exercised	Age
Dr. J. Joseph Kim Ph.D.	CEO, Pres & Director	1.03M	1.51M	48
Mr. Peter D. Kies	Chief Financial Officer	538.36k	N/A	54
Dr. Niranjan Y. Sardesai Ph.D.	Chief Operating Officer	575.44k	90.74k	49
Dr. Mark L. Bagarazzi M.D.	Chief Medical Officer	576.45k	N/A	56
Mr. Thomas S. Kim J.D.	Gen. Counsel and Corp. Sec.	N/A	N/A	N/A

Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company’s partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate Governance

Inovio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 6. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.